BI
BIOQ.US Bioqual Inc
- Market cap
- USD 27.7M
- P/E
- 11.8x
- P/B
- 1.00x
- ROE
- -6.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is BIOQ.US undervalued?
Graham numberBIOQ.US trades 27.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioqual Inc fundamental analysis
No fundamental analysis for Bioqual Inc yet.
Bioqual Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioqual Inc
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, imm…
Full company profileBioqual Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bioqual Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 36.6M | 35.9M | 39.5M | 46.4M | 57.7M | 66.2M | 62.7M | 58.6M | 48.9M | 39.9M | 40.6M |
| Gross Profit | 9.90M | 8.73M | 7.41M | 9.69M | 14.0M | 13.0M | 12.6M | 7.43M | -1.90M | 1.43M | 1.96M |
| Operating Income | 6.54M | 5.27M | 3.58M | 5.32M | 8.56M | 6.53M | 1.10M | -19.6K | -1.90M | -4.47M | -3.19M |
| EBITDA | 7.18M | 6.08M | 4.61M | 9.78M | 13.1M | 14.8M | 6.97M | 3.03M | 474K | -2.25M | 2.07M |
| Net Income | 3.96M | 3.66M | 2.83M | 4.23M | 6.33M | 5.26M | 836K | 483K | -1.05M | -4.17M | -1.98M |
| EPS | 4.44 | 4.10 | 3.17 | 4.73 | 7.08 | 5.88 | 0.93 | 0.54 | -1.17 | -4.66 | -2.21 |
| Balance Sheet | |||||||||||
| Total Assets | 22.8M | 26.3M | 28.3M | 49.5M | 53.4M | 63.3M | 61.3M | 56.6M | 57.1M | 68.4M | 67.4M |
| Total Liabilities | 3.84M | 4.26M | 3.75M | 21.4M | 19.9M | 25.7M | 23.7M | 18.9M | 21.0M | 36.0M | 35.5M |
| Shareholders' Equity | 18.9M | 22.0M | 24.6M | 28.2M | 33.5M | 37.7M | 37.6M | 37.6M | 36.2M | 32.4M | 31.9M |
| Cash & Short-term Investments | 9.29M | 10.2M | 9.21M | 10.3M | 7.72M | 2.18M | 7.28M | 15.6M | 17.9M | 16.0M | 16.5M |
| Total Debt | 567K | 250K | - | 16.1M | 14.6M | 18.7M | 18.6M | 3.59M | 16.5M | 32.7M | 31.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.39M | 3.71M | 1.70M | 4.08M | 2.15M | 313K | 8.23M | 9.36M | 2.94M | 351K | 2.11M |
| Capital Expenditure | 742K | 2.07M | 1.87M | 2.40M | 4.41M | 4.89M | 2.24M | 597K | 239K | 418K | 268K |
| Free Cash Flow | 4.65M | 1.64M | -170K | 1.67M | -2.26M | -4.57M | 5.99M | 8.76M | 2.71M | -66.8K | 1.85M |
| Ratios | |||||||||||
| ROE | 21.0% | 16.6% | 11.5% | 15.0% | 18.9% | 14.0% | 2.2% | 1.3% | -2.9% | -12.9% | -6.2% |
| ROA | 17.4% | 13.9% | 10.0% | 8.5% | 11.8% | 8.3% | 1.4% | 0.9% | -1.8% | -6.1% | -2.9% |
| Net Profit Margin | 10.8% | 10.2% | 7.2% | 9.1% | 11.0% | 8.0% | 1.3% | 0.8% | -2.1% | -10.4% | -4.9% |
| Debt to Equity | 0.03x | 0.01x | - | 0.57x | 0.44x | 0.50x | 0.49x | 0.10x | 0.46x | 1.01x | 1.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bioqual Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Oct 7, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | USD 447K | 0.50 | - |
| 2024 | USD 447K | 0.50 | 92.5% |
| 2023 | USD 894K | 1.00 | 107.0% |
| 2022 | USD 1.12M | 1.25 | 21.3% |
| 2021 | USD 984K | 1.10 | 15.6% |
| 2020 | USD 626K | 0.70 | 14.8% |
| 2019 | USD 537K | 0.60 | 19.0% |
| 2018 | USD 536K | 0.60 | 14.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Oct 30, 1997.
Who owns Bioqual Inc
Ownership data of Bioqual Inc is not available yet.
Bioqual Inc company profile
- Company name
- Bioqual Inc
- Ticker
- BIOQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- May
- Address
- 9620 Medical Center Drive, Rockville, MD, United States, 20850
- Phone
- 240 404 7654
- Website
- bioqual.com
About Bioqual Inc
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services. Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.
Bioqual Inc management
3- Dr. Hanne Andersen-Elyard Ph.D.President & Chief Scientific Officer
- Mr. Charles C. Kirk Jr., CPAChief Financial Officer
- Mr. Mitchell L. FranklinCOO & Secretary